WNT secretion is also targeted by some inhibitors like the inhibitor IWP-2 for treatment of cancers, especially pancreatic cancers with RNF43 mutations (69, 71, 72), whereas PORCN inhibitors WNT974 and ETC-159 are applicable to prevent mammary tumors and cancer stem cells (73–75). Here, RNF43 is linked to pancreatic neoplasm.